Previous 10 | Next 10 |
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has trig...
Few diseases have wreaked as much havoc as malaria. In 2019, there were an estimated 229 million malaria cases. More than 400,000 people worldwide die from the mosquito-borne disease every year. Roughly two-thirds of those deaths are kids aged 5 or younger. But now help is on the way. L...
LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc . (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced accept...
M&A speculation took the spotlight in Friday's pre-market action. Invesco (NYSE:IVZ) got a boost on reports that it was in talks for a potential merger with a unit of State Street (NYSE:STT). Agenus (NASDAQ:AGEN) also experienced pre-market strength, inspired by the release of clinical tr...
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...
Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies ...
LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections today announced t...
LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennif...
Agenus Inc. (NASDAQ:AGEN) traded at a new 52-week high today of $6.43. So far today approximately 8.4 million shares have been exchanged, as compared to an average 30-day volume of 3 million shares. In the past 52 weeks, shares of Agenus Inc. have traded between a low of $2.50 and a high...
Agenus Inc. (NASDAQ:AGEN) traded at a new 52-week high today of $6.36. So far today approximately 8.4 million shares have been exchanged, as compared to an average 30-day volume of 2.8 million shares. Agenus Inc. (NASDAQ:AGEN) defies analysts with a current price ($6.27) 7.9% above its a...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...